Grace Therapeutics, Inc. (GRCE) Balance Sheet
GRCE balance sheet, FY2026
March 31, 2026 · U.S. dollars$66.7M assets = $2.8M liabilities + $63.9M equity
Both columns are drawn to the same scale: what GRCE owns equals what it owes plus shareholders’ equity. Hover a block for its value.
GRCE financial health
Current ratio8.10
Comfortable · current assets cover current liabilities 8.10×
Equity / assets95.9%
Equity-funded · of assets funded by shareholders
Goodwill & intangibles73.9%
Mostly intangible · of total assets
Descriptive bands, not a rating. Fiscal FY2026.
GRCE balance sheet trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $25.5MFY2017 | $66.7MFY2026 | +11.3%/yr | |
| Total liabilities | $3.8MFY2017 | $2.8MFY2026 | −3.4%/yr | |
| Shareholders’ equity | $21.7MFY2017 | $63.9MFY2026 | +12.7%/yr | |
| Cash & short-term investments | $9.8MFY2017 | $17.0MFY2026 | +6.3%/yr | |
| Total debt | $1.4MFY2017 | $485,000FY2023 | −16.3%/yr | |
| Net cash (debt) | $8.4MFY2017 | $27.4MFY2023 | +$19.0M | |
| Working capital | $8.1MFY2017 | $15.2MFY2026 | +$7.2M | |
| Book value per share | $17.63FY2022 | $3.87FY2026 | −31.6%/yr | |
| Current ratio | 4.76FY2017 | 8.10FY2026 | +3.33 | |
| Debt / equity | 0.06FY2017 | 0.01FY2023 | −0.06 | |
| Shares outstanding | 6.1MFY2022 | 16.5MFY2026 | +28.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GRCE assets
Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current
GRCE liabilities and equity
Current liabilitiesLong-term debtOther long-term liabilitiesEquity
GRCE debt vs cash
Total debtCash & ST investmentsNet cash (debt)
Debt includes short- and long-term borrowings and, where reported, lease obligations.
GRCE balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $17.0M | $22.1M | $23.0M | $27.9M | $43.7M | $76.3M | $20.1M | $25.8M | $6.4M | $9.8M |
| Cash & equivalents | $17.0M | $22.1M | $23.0M | $27.9M | $30.3M | $64.0M | $20.1M | $16.9M | $6.4M | — |
| Short-term investments | — | — | $0 | $15,000 | $13.3M | $12.3M | $9.8M | $8.9M | — | — |
| Receivables | $20,000 | $126,000 | $722,000 | $802,000 | $548,000 | $665,810 | $771,811 | $1.6M | $759,260 | $206,167 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $0 |
| Other current assets | $383,000 | $453,000 | $283,000 | $598,000 | $1.3M | $1.4M | $1.7M | $615,576 | $223,386 | $209,171 |
| Total current assets | $17.4M | $22.7M | $24.0M | $29.3M | $45.5M | $78.4M | $22.6M | $28.0M | $7.4M | $10.2M |
| Property, plant & equipment (net) | $8,000 | $15,000 | $24,000 | $567,000 | $315,000 | $108,037 | $2.9M | $2.1M | $2.2M | $2.9M |
| Goodwill & intangible assets | $49.3M | $49.3M | $49.3M | $49.3M | $82.8M | $0 | $6.0M | $6.4M | $7.8M | $12.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $839,665 | $437,000 | $449,897 | $3 |
| Total assets | $66.7M | $72.0M | $73.3M | $79.1M | $128.6M | $78.5M | $32.3M | $36.9M | $17.8M | $25.5M |
| Liabilities | ||||||||||
| Accounts payable | $702,000 | $601,000 | $1.0M | $1.2M | $3.2M | $144,468 | $2.4M | $3.0M | $2.6M | — |
| Short-term debt | — | — | — | $75,000 | $104,000 | $108,037 | $228,998 | $1.4M | — | — |
| Total current liabilities | $2.1M | $1.9M | $1.7M | $3.4M | $3.3M | $2.0M | $10.5M | $13.7M | $5.2M | $2.1M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | $0 | $485,000 | $295,000 | $86,000 | — | — | — | — |
| Other long-term liabilities | $612,000 | $3.5M | $9.9M | $7.8M | $17.1M | $6.6M | $3.5M | $12.2M | $6.2M | $1.6M |
| Total liabilities | $2.8M | $5.4M | $11.6M | $11.2M | $20.4M | $8.5M | $13.9M | $25.9M | $11.4M | $3.8M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $261.0M | $258.3M | $258.0M | $247.7M | $194.3M | $110.9M | $56.8M | $66.6M |
| Retained earnings (deficit) | −$228.5M | −$220.7M | −$211.1M | −$198.3M | −$155.8M | −$183.4M | −$178.6M | −$100.8M | −$56.0M | −$50.9M |
| Accumulated other comprehensive income | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$8.0M | −$11.1M | — | — | $309,250 |
| Total shareholders' equity | $63.9M | $66.6M | $61.7M | $68.0M | $108.3M | $69.9M | $18.4M | $11.0M | $6.4M | $21.7M |
| Key figures | ||||||||||
| Total debt | — | — | — | $485,000 | $295,000 | $108,037 | $207,795 | $1.4M | $1.2M | $1.4M |
| Net cash (debt) | — | — | — | $27.4M | $43.4M | $76.2M | $19.9M | $24.4M | $5.1M | $8.4M |
| Working capital | $15.2M | $20.8M | $22.3M | $25.9M | $42.3M | $76.4M | $12.1M | $14.3M | $2.2M | $8.1M |
| Tangible book value | $14.6M | $17.3M | $12.5M | $18.7M | $25.5M | $69.9M | $12.4M | $4.7M | −$1.4M | $9.3M |
| Book value per share | $3.87 | $5.51 | $6.48 | $9.14 | $17.63 | — | — | — | — | — |
| Shares outstanding | 16.5M | 12.1M | 9.5M | 7.4M | 6.1M | — | — | — | — | — |
| Current ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 | 39.50 | 2.16 | 2.05 | 1.42 | 4.76 |
| Quick ratio | 7.92 | 11.53 | 14.09 | 8.41 | 13.56 | 38.80 | 2.00 | 2.00 | 1.37 | 4.67 |
| Debt / equity | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.12 | 0.20 | 0.06 |
| Equity / assets | 95.9% | 92.5% | 84.2% | 85.9% | 84.2% | 89.1% | 56.9% | 29.9% | 35.8% | 85.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $13.8M | $17.0M | $18.7M | $16.9M | $20.0M | $22.1M | $11.1M | $15.2M | $19.4M | $23.0M | $25.1M | $27.0M |
| Cash & equivalents | $13.8M | $17.0M | $18.7M | $16.9M | $20.0M | $22.1M | $11.1M | $15.2M | $19.4M | $23.0M | $18.5M | $27.0M |
| Short-term investments | — | — | — | — | — | — | — | $15,000 | $15,000 | $0 | $6.6M | $15,000 |
| Receivables | $20,000 | $20,000 | $20,000 | $20,000 | $20,000 | $126,000 | $301,000 | $415,000 | $398,000 | $722,000 | $959,000 | $837,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $557,000 | $383,000 | $519,000 | $416,000 | $500,000 | $453,000 | $583,000 | $477,000 | $622,000 | $283,000 | $811,000 | $1.0M |
| Total current assets | $14.3M | $17.4M | $19.2M | $17.3M | $20.5M | $22.7M | $11.9M | $16.1M | $20.4M | $24.0M | $26.9M | $28.9M |
| Property, plant & equipment (net) | $7,000 | $8,000 | $11,000 | $12,000 | $14,000 | $15,000 | $18,999 | $21,000 | $23,000 | $24,000 | $34,999 | $57,000 |
| Goodwill & intangible assets | $35.7M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M | $49.3M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $0 | $0 | $0 | $1 | $0 |
| Total assets | $50.1M | $66.7M | $68.5M | $66.6M | $69.8M | $72.0M | $61.2M | $65.3M | $69.7M | $73.3M | $76.2M | $78.2M |
| Liabilities | ||||||||||||
| Accounts payable | $408,000 | $702,000 | $156,422 | $459,000 | $1.3M | $601,000 | $665,000 | $1.7M | $1.5M | $1.0M | $913,000 | $685,000 |
| Short-term debt | — | — | — | — | — | — | — | — | — | — | $24,000 | $46,000 |
| Total current liabilities | $1.2M | $2.1M | $1.3M | $1.2M | $2.3M | $1.9M | $2.0M | $2.7M | $2.6M | $1.7M | $1.8M | $1.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | — | — | — | — | $0 | $24,000 | $46,000 |
| Other long-term liabilities | $612,000 | $612,000 | $2.3M | $2.5M | $3.9M | $3.5M | $7.1M | $6.5M | $7.8M | $9.9M | $9.7M | $10.1M |
| Total liabilities | $1.9M | $2.8M | $3.6M | $3.8M | $6.3M | $5.4M | $9.1M | $9.2M | $10.4M | $11.6M | $11.5M | $11.5M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $261.0M | $261.0M | $261.0M | $261.0M | $261.0M |
| Retained earnings (deficit) | −$244.3M | −$228.5M | −$227.3M | −$225.0M | −$224.0M | −$220.7M | −$221.3M | −$217.2M | −$213.7M | −$211.1M | −$208.0M | −$205.6M |
| Accumulated other comprehensive income | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M | −$6.0M |
| Total shareholders' equity | $48.2M | $63.9M | $64.9M | $62.8M | $63.5M | $66.6M | $52.1M | $56.1M | $59.4M | $61.7M | $64.7M | $66.7M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | — | — | — | $24,000 | $46,000 |
| Net cash (debt) | — | — | — | — | — | — | — | — | — | — | $25.1M | $27.0M |
| Working capital | $13.1M | $15.2M | $17.9M | $16.1M | $18.2M | $20.8M | $10.0M | $13.4M | $17.8M | $22.3M | $25.1M | $27.5M |
| Tangible book value | $12.5M | $14.6M | $15.6M | $13.6M | $14.3M | $17.3M | $2.9M | $6.9M | $10.1M | $12.5M | $15.4M | $17.5M |
| Book value per share | $2.79 | $3.87 | $3.83 | $3.94 | $3.99 | $4.76 | $4.53 | $4.88 | $5.43 | $6.04 | $5.62 | $8.84 |
| Shares outstanding | 17.3M | 16.5M | 16.9M | 15.9M | 15.9M | 14.0M | 11.5M | 11.5M | 10.9M | 10.2M | 11.5M | 7.6M |
| Current ratio | 11.47 | 8.10 | 14.96 | 13.89 | 8.87 | 11.77 | 6.06 | 6.01 | 7.86 | 14.26 | 15.19 | 20.68 |
| Quick ratio | 11.02 | 7.92 | 14.56 | 13.56 | 8.65 | 11.53 | 5.76 | 5.83 | 7.62 | 14.09 | 14.73 | 19.93 |
| Debt / equity | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 |
| Equity / assets | 96.3% | 95.9% | 94.7% | 94.4% | 91.0% | 92.5% | 85.2% | 85.9% | 85.1% | 84.2% | 84.9% | 85.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed June 18, 2026); data from EODHD.
GRCE financial position
At the end of fiscal 2026 (March 31, 2026), Grace Therapeutics had total assets of $66.7 million (down 7.4% from a year earlier), total liabilities of $2.8 million and shareholders' equity of $63.9 million. Its current ratio was 8.10. In the latest quarter (ended June 30, 2026) total assets were $50.1 million and equity $48.2 million.
Related: GRCE income statement, GRCE cash flow statement, GRCE key metrics. See the GRCE stock overview for the latest quote and news.
GRCE balance sheet FAQ
What are Grace Therapeutics's total assets?
Grace Therapeutics reported total assets of $66.7 million at the end of fiscal 2026 (March 31, 2026), compared with $72.0 million a year earlier.
How much cash does Grace Therapeutics have?
Grace Therapeutics held $17.0 million in cash and short-term investments at the end of fiscal 2026.
What is Grace Therapeutics's book value?
Grace Therapeutics's shareholders' equity (book value) was $63.9 million at the end of fiscal 2026, or $3.87 per share.
What is Grace Therapeutics's current ratio?
Grace Therapeutics had current assets of $17.4 million and current liabilities of $2.1 million, a current ratio of 8.10 (it can cover its short-term obligations).
How much goodwill does Grace Therapeutics have?
Grace Therapeutics carried $49.3 million of goodwill and intangible assets, 73.9% of total assets, at the end of fiscal 2026.